Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognition - PubMed
6 hours ago
- #Alzheimer's disease
- #biomarkers
- #cognitive decline
- Study examines the temporal evolution of plasma p-tau217, amyloid PET, tau PET, and cognition in Alzheimer's disease.
- Involves 2369 Mayo Clinic Study of Aging (MCSA) and 1591 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants.
- Non-linear mixed effects models used to estimate individual progression relative to population mean.
- Moderate associations found between biomarkers and cognitive decline in MCSA; stronger in ADNI cohort.
- Plasma p-tau217 accounted for 16% of variability in cognitive decline timing in MCSA and 64% in ADNI.
- APOE ε4 carriership linked to earlier biomarker progression.
- Cognitive abnormality (AVLT) followed biomarkers up to age 90, after which it preceded tau biomarkers.
- Findings support plasma p-tau217 as a useful marker of disease progression, comparable to amyloid PET.
- Temporal ordering of biomarkers and cognitive decline aligns with expectations (amyloid, tau, cognition) until age 90.